Gardasil for boys is not cost-effective, study says

10/9/2009 | Los Angeles Times (tiered subscription model)

A government campaign to give boys Gardasil, a cervical cancer vaccine that protects against human papillomavirus, would be no more effective in reducing HPV-related diseases and cost much more than a vaccination campaign directed at girls, Harvard University researchers concluded. The findings come as the FDA considers allowing boys to receive Gardasil, made by Merck & Co.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD